Scleroderma, An Issue of Rheumatic Disease Clinics, 1st Edition
Author :
By Maureen D. Mayes, MD, MPH
Scleroderma, or systemic sclerosis, is a chronic connective tissue disease generally classified as one of the autoimmune rheumatic diseases. Hardening of the skin is one of the most visible manifestations of the disease. It’s estimated that about 3
...view more
Scleroderma, or systemic sclerosis, is a chronic connective tissue disease generally classified as one of the autoimmune rheumatic diseases. Hardening of the skin is one of the most visible manifestations of the disease. It’s estimated that about 300,000 Americans have scleroderma. About one third of those people have the systemic form of scleroderma. Since scleroderma presents with symptoms similar to other autoimmune diseases, diagnosis is difficult. This issue will cover: The Genetic Basis of SSc: Genetics, Epigenetics, Mechanisms of Pathogenesis – linking fibrosis, vasculopathy and immune dysregulation, The Role of Autoantibodies in Diagnosis and Prognosis/survival; Managing Raynaud’s phenomenon and ischemic ulcers, managing SSc Lung Disease, Monitoring for and Managing Pulmonary Arterial Hypertension, and many more!
Scleroderma, or systemic sclerosis, is a chronic connective tissue disease generally classified as one of the autoimmune rheumatic diseases. Hardening of the skin is one of the most visible manifestations of the disease. It’s estimated that about 300,000 Americans have scleroderma. About one third of those people have the systemic form of scleroderma. Since scleroderma presents with symptoms similar to other autoimmune diseases, diagnosis is difficult. This issue will cover: The Genetic Basis of SSc: Genetics, Epigenetics, Mechanisms of Pathogenesis – linking fibrosis, vasculopathy and immune dysregulation, The Role of Autoantibodies in Diagnosis and Prognosis/survival; Managing Raynaud’s phenomenon and ischemic ulcers, managing SSc Lung Disease, Monitoring for and Managing Pulmonary Arterial Hypertension, and many more!
Author Information
By Maureen D. Mayes, MD, MPH, Professor of Internal Medicine
Elizabeth Bidgood Chair in Rheumatology
Division of Rheumatology and Clinical Immunogenetics
University of Texas – Houston Medical School
By Maureen D. Mayes, MD, MPH, Professor of Internal Medicine
Elizabeth Bidgood Chair in Rheumatology
Division of Rheumatology and Clinical Immunogenetics
University of Texas – Houston Medical School
https://www.asia.elsevierhealth.com/scleroderma-an-issue-of-rheumatic-disease-clinics-9780323393546.html294504Scleroderma, An Issue of Rheumatic Disease Clinicshttps://www.asia.elsevierhealth.com/media/catalog/product/9/7/9780323393546_7.jpg89.0998.99USDInStock/Medicine & Surgery/Rheumatology/Clinics/Medicine/Rheumatology/Clinics/Clinics/Medicine/Rheumatology/Japan Titles43350904388725505455550546665255041525983552631601418269243350884886536505455351451205259833<p>Scleroderma, or systemic sclerosis, is a chronic connective tissue disease generally classified as one of the autoimmune rheumatic diseases. Hardening of the skin is one of the most visible manifestations of the disease. It’s estimated that about 300,000 Americans have scleroderma. About one third of those people have the systemic form of scleroderma. Since scleroderma presents with symptoms similar to other autoimmune diseases, diagnosis is difficult. This issue will cover: The Genetic Basis of SSc: Genetics, Epigenetics, Mechanisms of Pathogenesis – linking fibrosis, vasculopathy and immune dysregulation, The Role of Autoantibodies in Diagnosis and Prognosis/survival; Managing Raynaud’s phenomenon and ischemic ulcers, managing SSc Lung Disease, Monitoring for and Managing Pulmonary Arterial Hypertension, and many more!</p> <p>Scleroderma, or systemic sclerosis, is a chronic connective tissue disease generally classified as one of the autoimmune rheumatic diseases. Hardening of the skin is one of the most visible manifestations of the disease. It’s estimated that about 300,000 Americans have scleroderma. About one third of those people have the systemic form of scleroderma. Since scleroderma presents with symptoms similar to other autoimmune diseases, diagnosis is difficult. This issue will cover: The Genetic Basis of SSc: Genetics, Epigenetics, Mechanisms of Pathogenesis – linking fibrosis, vasculopathy and immune dysregulation, The Role of Autoantibodies in Diagnosis and Prognosis/survival; Managing Raynaud’s phenomenon and ischemic ulcers, managing SSc Lung Disease, Monitoring for and Managing Pulmonary Arterial Hypertension, and many more!</p>00add-to-cart97803233935462015ProfessionalBy Maureen D. Mayes, MD, MPH20151Book152w x 229h (6.00" x 9.00")Elsevier0Aug 3, 2015IN STOCKBy <STRONG>Maureen D. Mayes</STRONG>, MD, MPH, Professor of Internal Medicine
Elizabeth Bidgood Chair in Rheumatology
Division of Rheumatology and Clinical Immunogenetics
University of Texas – Houston Medical SchoolClinicsClinicsThe Clinics: Internal MedicineUnited StatesNoNoNoNoPlease SelectPlease SelectPlease Select
